25 Apr 2023
27 Apr 2023
Rs. 4326.36 Cr
08 May 2023
₹ 1026 to ₹1080 per share
Mankind Pharma is India’s fourth largest pharmaceutical company in terms of Domestic Sales and third largest in terms of sales volume for MAT December 2022. It engages in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products such as vitamin and mineral supplements, antacid powdersetc.
Objective of the Mankind Pharma IPO: The net proceeds from the issue will be used for: • Carry out the Offer for Sale of 40,058,844 Equity Shares by the Selling Shareholders • Achieve the benefits of listing the Equity Shares on the Stock Exchanges
The Mankind Pharma IPO lot size is 13 shares. A retail-individual investor can apply for up to 14 lots (182 shares or ₹196,560)
Mankind Pharma IPO is promoted by Ramesh Juneja, Rajeev Juneja, Sheetal Arora, Ramesh Juneja Family Trust, Rajeev Juneja Family Trust, and Prem Sheetal Family Trust.
The allotment date of Mankind Pharma IPO is set for 3rd May.
Kotak Mahindra Capital, Jefferies, IIFL Capital, Axis Capital, and JP Morgan are the lead book managers to the issue.